Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

Current Medical Research and Opinion

Volumn 25, Issue 10, 2009, Pages 2507-2514

  Alba, Maria ^a   Sheng, D ^a   Guan, Y ^a   Williams Herman, D ^a   Larson, P ^a   Sachs, J R ^a   Thornberry, N ^a   Herman, G ^a   Kaufman, K D ^a   Goldstein, B J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitor; DPP IV; Incretin; MK 0431

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; PLACEBO; SITAGLIPTIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DILUTION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 70349325850     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903209514     Document Type: Article

References (13)

1. Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-496 (Pubitemid 351294398)
2. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-151
3. Herman GA, Stevens C, Van DK, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-688
4. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006;28:55-72 (Pubitemid 43254990)
5. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619 (Pubitemid 44833446)
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
7. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329-1339 (Pubitemid 46998442)
8. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637 (Pubitemid 44912190)
9. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571
10. 1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278
11. 1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023-2029
12. Segel IH. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. New York: Wiley-Interscience, 1975
13. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30:513-527